Forest Laboratories Inc.

Jul 10, 09 NEW STORY 09:15 ET Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation      Jul 06, 09 09:00 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2010 First Quarter Earnings      Jun 19, 09 13:25 ET Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization      May 31, 09 11:45 ET Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation      May 12, 09 08:00 ET Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide      Apr 21, 09 08:00 ET Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation      Apr 20, 09 08:00 ET Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)      Apr 06, 09 08:52 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Fourth Quarter Earnings      Mar 20, 09 13:38 ET Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents      Mar 10, 09 06:09 ET USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R)      Mar 06, 09 08:00 ET Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)      02:30 ET Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program      Feb 26, 09 00:07 ET Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government      Jan 20, 09 08:00 ET Forest Laboratories, Inc. Reports Q3'09 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees      Jan 14, 09 19:24 ET Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia      Jan 05, 09 17:00 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings      Dec 22, 08 08:00 ET Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression      Dec 17, 08 09:03 ET Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares      Dec 08, 08 08:00 ET Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia      Dec 03, 08 17:04 ET Forest Laboratories Responds To Unsolicited Mini-Tender Offer      Nov 24, 08 17:00 ET USPTO Confirms Validity of Bystolic(R) Patent      Oct 27, 08 08:00 ET Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA      Oct 23, 08 08:00 ET Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes      Oct 21, 08 08:00 ET Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80      Oct 20, 08 08:00 ET FDA Defers Final Action on milnacipran New Drug Application      Oct 07, 08 08:00 ET Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation      Oct 06, 08 11:35 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings   Oct 01, 08 16:43 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings      Sep 30, 08 02:00 ET Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder      Sep 23, 08 18:07 ET Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference      Sep 15, 08 08:45 ET Forest Laboratories, Inc. Appoints Frank Murdolo, Vice President - Investor Relations      Sep 04, 08 08:00 ET USPTO Office Action in the Reexamination of U.S. Patent No. 6,545,040      Sep 03, 08 02:00 ET Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)      Jul 30, 08 13:30 ET New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation      Jul 22, 08 08:00 ET Forest Laboratories, Inc. Reports Fiscal First Quarter 2009 Earnings Per Share of $0.79, Including $0.08 per Share Charge for Agreement Termination      Jun 30, 08 16:42 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings      Jun 19, 08 07:50 ET Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections      May 20, 08 18:30 ET Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results      11:30 ET Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD      May 16, 08 15:55 ET Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress      May 15, 08 13:22 ET Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress      May 12, 08 08:45 ET Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement      May 07, 08 12:00 ET Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents      Apr 15, 08 07:50 ET Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment      Apr 07, 08 13:33 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings      Mar 19, 08 08:12 ET Forest Laboratories Announces Resignation of Ivan Gergel, MD      Mar 04, 08 18:04 ET Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies      Feb 27, 08 16:17 ET Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement      Feb 05, 08 08:02 ET Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation      Jan 25, 08 12:39 ET Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement      Jan 22, 08 07:30 ET Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor      Jan 15, 08 07:50 ET Forest Laboratories, Inc. Reports Q3'08 Diluted Earnings Per Share of $0.96. Raises FY2008 EPS Guidance Range to $3.35-$3.45 Excluding $0.15 per Share Licensing Charge      Jan 10, 08 17:05 ET Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Lawsuits Against Several Companies for Patent Infringement      Jan 04, 08 08:35 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Third Quarter Earnings      Dec 31, 07 07:05 ET Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome      Dec 18, 07 06:30 ET Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension      Dec 13, 07 16:20 ET Forest Laboratories Receives Notification of ANDA Filings for Generic Equivalents of Namenda(R)      Nov 29, 07 09:00 ET Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression      Nov 08, 07 08:30 ET Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show      Nov 02, 07 14:10 ET Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran      Oct 16, 07 08:05 ET Forest Laboratories Reports Earnings Per Share of $0.71 for Q2'08 Including $0.15 Charge Net of Tax for Licensing Charge      Oct 15, 07 16:10 ET Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia      Oct 08, 07 12:38 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings   Sep 18, 07 06:05 ET Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress      Sep 17, 07 08:03 ET Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration      Sep 05, 07 12:24 ET Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision      Aug 13, 07 14:39 ET Forest Laboratories, Inc. Expands Share Repurchase Program      Jul 17, 07 08:07 ET Forest Laboratories, Inc. Reports Fiscal First Quarter 2008 Earnings Per Share Of $0.83      Jul 03, 07 14:27 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 First Quarter Earnings      May 31, 07 16:15 ET Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo      May 22, 07 16:56 ET Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome      May 21, 07 08:00 ET Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy      May 01, 07 10:49 ET Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol      Apr 24, 07 07:58 ET Forest Laboratories, Inc. Reports Fiscal Year 2007 Fourth Quarter Revenues of $885,000,000, Reported EPS Loss of ($0.75) and Adjusted EPS of $0.74*, Excluding the Effect of the Cerexa Acquisition      Apr 09, 07 15:30 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2007 Fourth Quarter Earnings   Feb 12, 07 16:28 ET Forest Laboratories Announces Rule 144 Sale by Executive Officer      Feb 06, 07 17:30 ET Forest Laboratories Announces Termination of Agreement for Faropenem      Jan 16, 07 08:05 ET Forest Laboratories, Inc. Reports Q3'07 Diluted Earnings Per Share of $0.78      Jan 11, 07 16:03 ET Forest Laboratories Announces Completion of Acquisition of Cerexa, Inc.      Jan 05, 07 08:55 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2007 Third Quarter Earnings      Dec 14, 06 08:29 ET Forest Laboratories Announces Acquisition of Cerexa, Inc.      Dec 06, 06 08:00 ET Lexapro(R) Demonstrated Significance on Prospectively Defined Efficacy Parameter and Was Better Tolerated Than Cymbalta(R) in Treatment of Depression      Oct 27, 06 23:08 ET Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2      Oct 25, 06 08:52 ET Patient Recruitment for Desmoteplase Phase IIB/III Stroke Study DIAS-2 Placed on Hold      Oct 17, 06 07:57 ET Forest Laboratories Reports Earnings Per Share of $0.75 for Q2'07      Oct 05, 06 16:51 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2007 Second Quarter Earnings      Sep 07, 06 08:00 ET Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. Olanoff as President and Chief Operating Officer      Jul 18, 06 07:58 ET Forest Laboratories, Inc. Reports Fiscal First Quarter 2007 Results      Jul 13, 06 20:05 ET Forest Announces Federal Court Upholds Lexapro(R) Patent      Jul 11, 06 08:55 ET Forest Laboratories, Inc. and H. Lundbeck A/S File Lawsuit Against Caraco Pharmaceutical Laboratories, Ltd. for Patent Infringement      Jul 10, 06 14:14 ET Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2007 First Quarter Earnings      May 18, 06 14:26 ET Forest Laboratories Announces Nesli Basgoz, M.D. Named to Board of Directors      14:25 ET Forest Laboratories, Inc. Announces New Share Repurchase Program      Apr 25, 06 08:07 ET Forest Laboratories, Inc. Reports Q4'06 Diluted Earnings Per Share of $0.28 Including $0.37 Per Share Charge for Licensing and Milestone Payments      Apr 12, 06 16:05 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2006 Fourth Quarter Earnings      Apr 10, 06 08:00 ET Forest and Almirall Announce a Development and Marketing Collaboration Agreement on New Therapy for COPD      Mar 02, 06 08:31 ET Forest Laboratories Receives Patent Term Extension for Lexapro      Feb 23, 06 08:35 ET Replidyne and Forest Laboratories Announce FDA Acceptance for Review of New Drug Application for Oral Antibiotic Faropenem Medoxomil      Feb 15, 06 18:08 ET Forest Laboratories Revises Research and Development Spending Projection to Account for Upfront Payments for Two Recent In-Licensing Transactions      Feb 13, 06 08:20 ET Replidyne and Forest Laboratories Announce Faropenem Medoxomil Licensing Agreement      Jan 17, 06 08:09 ET Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share of $0.57 Including $0.05 Per Share Licensing Payment      Jan 05, 06 08:12 ET Forest Laboratories, Inc. and Cypress Bioscience, Inc. to Commence Third Milnacipran Phase III Trial      Jan 04, 06 12:38 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2006 Third Quarter Earnings      Nov 28, 05 16:10 ET Gedeon Richter and Forest Laboratories Expand Relationship with Two New Collaborations for CNS Compounds      Oct 26, 05 16:13 ET Forest Laboratories and H. Lundbeck A/S Announce Lexapro Patent Litigation Trial Date Rescheduled to March 15, 2006      Oct 18, 05 08:15 ET Forest Laboratories Announces Executives Intend to Exercise Options With Intent to Hold Shares      08:12 ET Forest Laboratories Reports Earnings Per Share of $0.59 for Q2'06      Oct 06, 05 08:01 ET Forest Laboratories and Lundbeck Enter Into Settlement Agreement With Alphapharm Related to Lexapro Patent Litigation      Oct 05, 05 16:06 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2006 Second Quarter Earnings      Sep 28, 05 20:16 ET Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia      Aug 26, 05 12:00 ET Forest Laboratories Updates Lexapro Patent Litigation Status      Aug 18, 05 17:10 ET Oral Solution Formulation of Namenda(R), the Only FDA-Approved Oral Solution for Moderate to Severe Alzheimer's Disease, Now Available      Jul 25, 05 12:31 ET Forest Laboratories Announces FDA Decision on Supplemental New Drug Application for Namenda(R)      Jul 19, 05 08:04 ET Forest Laboratories, Inc. Reports Fiscal First Quarter 2006 Results      Jul 14, 05 13:38 ET Forest Laboratories, Inc. to Continue Clinical Development of Neramexane Based on New Clinical Trial Results      Jul 11, 05 14:11 ET Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2006 First Quarter Earnings      Jul 01, 05 08:05 ET Phillip M. Satow Resigns from Forest Laboratories Board of Directors      May 19, 05 08:57 ET Forest Laboratories, Inc. Names Ivan Gergel, M.D., Senior Vice-President and President of Forest Research Institute      May 10, 05 16:30 ET Forest Laboratories, Inc. Announces New Share Repurchase Program      Apr 28, 05 16:41 ET Forest Laboratories Announces Court Sets New Trial Date for Lexapro Patent Challenge      Apr 19, 05 07:58 ET Forest Laboratories Reports Fiscal Fourth Quarter 2005 Results and Provides Earnings Per Share Guidance for Fiscal 2006      Apr 11, 05 12:56 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2005 Fourth Quarter Earnings      Apr 06, 05 08:23 ET Forest Laboratories Issues Revised Estimate for Q4'05 Earnings Per Share      Mar 30, 05 16:10 ET Forest Laboratories, Inc. Receives Non-Approvable Letter for Social Anxiety Disorder Indication for Lexapro(R)   Mar 21, 05 08:05 ET New COMBUNOX(TM) (Oxycodone HCl and Ibuprofen) Tablets (CII) Now Available for the Short-Term Treatment of Acute, Moderate to Severe Pain      Mar 01, 05 16:10 ET Forest Laboratories, Inc. Receives Non-Approvable Letter for Panic Disorder Indication for Lexapro(R)      Feb 09, 05 10:11 ET Forest Laboratories Starts Confirmatory Study of Desmoteplase A Novel Investigational Treatment For Acute, Ischemic Stroke      08:05 ET Forest Laboratories Starts Confirmatory Study of Desmoteplase A Novel Investigational Treatment For Acute, Ischemic Stroke      Feb 08, 05 09:30 ET Forest Laboratories, Inc. Announces Launch of Clinical Trial Registry - http://www.forestclinicaltrials.com      Jan 18, 05 08:05 ET Forest Laboratories, Inc. Reports Diluted Earnings Per Share of $0.70 for 3Q'05      Jan 07, 05 12:59 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2005 Third Quarter Earnings      Jan 04, 05 16:27 ET Forest Laboratories to Exceed Fiscal 2005 Third Quarter Mean Earnings Per Share Estimate      Dec 14, 04 08:05 ET Forest Laboratories Expands Share Repurchase Program      Nov 26, 04 16:21 ET FDA Approves Combunox(TM) (Oxycodone HCl and Ibuprofen) Tablets (CII) for the Short-Term Treatment Of Acute, Moderate to Severe Pain      Nov 22, 04 16:10 ET Gedeon Richter and Forest Laboratories Announce Collaboration Agreement on Atypical Antipsychotic for Schizophrenia, Bipolar Mania and Other Psychiatric Disorders      Nov 15, 04 08:10 ET FDA Accepts Supplemental New Drug Application Filing to Expand Namenda's(R) Indication to Include Treatment of Mild Alzheimer's Disease      Nov 02, 04 08:01 ET Forest Laboratories Updates Lercanidipine Development      Nov 01, 04 16:17 ET Forest Laboratories Revises FY2005 Earnings Guidance      Oct 18, 04 08:07 ET Forest Laboratories Reports Earnings Per Share of $.79 for 2Q'05; Offers Updated Fiscal 2005 EPS Guidance      Oct 12, 04 16:15 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2005 Second Quarter Earnings      Oct 04, 04 16:30 ET Forest Laboratories to Exceed Fiscal 2005 Second and Third Quarter Mean Earnings Per Share Estimates      Sep 27, 04 08:50 ET Forest Laboratories Appoints Francis Perier as Senior Vice President - Finance and Chief Financial Officer   Sep 23, 04 08:03 ET Glenmark Pharmaceuticals and Forest Laboratories Announce Collaboration Agreement on PDE4 Inhibitor for Asthma and COPD      Sep 08, 04 14:23 ET Forest Laboratories Announces Adoption of On-line Registry for Clinical Studies; Attorney General Agrees to Close Inquiry      Sep 07, 04 17:41 ET Forest Laboratories Announces Adoption of On-line Registry for Clinical Studies; Attorney General Agrees to Close Inquiry      Aug 31, 04 16:11 ET Forest Announces That Neramexane Did Not Demonstrate Statistical Significance in Recently Completed Phase III Trial in Patients with Moderate to Severe Alzheimer's Disease      Aug 26, 04 08:55 ET Forest Laboratories Submits Response for Lexapro(R) for Panic Disorder      Jul 20, 04 08:04 ET Forest Laboratories Reports Fiscal First Quarter Earnings of $.60 Per Share      08:04 ET Forest Laboratories, Inc. Announces Share Repurchase Program      Jul 13, 04 11:38 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2005 First Quarter Earnings      Jul 06, 04 08:04 ET Forest Laboratories, Inc. and PAION GmbH Announce Development and Marketing Agreement for Desmoteplase - Novel Investigational Treatment for Acute Stroke      Jun 29, 04 16:46 ET Forest Announces Request for Information From New York State Office of the Attorney General      Jun 24, 04 16:12 ET Forest Discusses Disclosure of Citalopram Clinical Trial Data in Children and Adolescents      16:11 ET Forest Announces Results of Recently Completed Lexapro(R) Pediatric Depression Clinical Trial      May 06, 04 18:39 ET Depressed Patients Showed Improvement with Lexapro(TM) After Failure with Initial SSRI Treatment      17:21 ET Namenda(TM) (memantine HCl) Provides Functional and Behavioral Benefits in Patients with Moderate to Severe Alzheimer's Disease      Apr 28, 04 09:11 ET New Data Highlight Positive Effect of Namenda(TM) on Brain Activity in Patients With Mild to Moderate Alzheimer's Disease   Apr 20, 04 08:06 ET Forest Laboratories Reports Earnings Per Share of $0.38 for Fiscal Fourth Quarter   Apr 16, 04 14:52 ET Forest Laboratories Receives Notification of ANDA Filing For a Generic Equivalent of Lexapro(R)      Apr 14, 04 08:25 ET Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2004 Fourth Quarter and Full Year Earnings      Mar 18, 04 16:47 ET Lexapro(R) as Effective as Paxil(R) and Well Tolerated in the Treatment of Generalized Anxiety Disorder      Mar 15, 04 16:33 ET Lexapro(R) as Effective as Paxil(R) and Well Tolerated in the Treatment of Generalized Anxiety Disorder      08:31 ET ChemoCentryx and Forest Laboratories to Collaborate on Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics   Feb 23, 04 17:17 ET Namenda(TM) Shows Benefit in Behavioral Disturbances Associated With Moderate to Severe Alzheimer's Disease   17:05 ET Researchers Report Namenda(TM) Provides Significant Benefits as Monotherapy to Patients With Mild to Moderate Alzheimer's Disease   Jan 29, 04 08:55 ET Forest Laboratories Receives Subpoena on Celexa      Jan 20, 04 16:19 ET JAMA Reports Alzheimer's Patients Treated With Combination of Namenda(TM) (Memantine HCl) and Donepezil Experienced Significant Benefits Compared to Donepezil Alone      09:33 ET Forest Laboratories Reports Record Earnings Per Share of $0.60 for 3Q'04      Jan 14, 04 16:13 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2004 Third Quarter Earnings      Jan 13, 04 08:05 ET Namenda(TM) (memantine HCl), First Drug Approved For Treatment of Moderate to Severe Alzheimer's Disease Now Available Nationwide      Jan 09, 04 11:04 ET Forest Laboratories to Exceed Fiscal 2004 Third Quarter Consensus and Guides Full Year to Top End of Previous Guidance      11:03 ET Cypress Bioscience, Inc., Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Development and Marketing Agreement for Milnacipran      Jan 07, 04 08:06 ET Namenda(TM) (Memantine HCl) Mild to Moderate Alzheimer's Disease Studies Reported Today Forest Laboratories to Seek Approval for Mild to Moderate Indication By Mid-Year   Dec 18, 03 14:42 ET Lexapro(TM) Receives FDA Approval for the Treatment of Generalized Anxiety Disorder      Dec 10, 03 13:00 ET Starting Dose of Lexapro(TM) as Effective as Optimally Dosed Zoloft(R) in the Treatment of Major Depressive Disorder      Nov 12, 03 16:43 ET Long-Term Treatment With Aerospan(TM) Has No Effect On Growth In Children With Mild Asthma      Oct 27, 03 08:53 ET Forest Laboratories Announces Rule 144 Sale by Executive Officer      Oct 22, 03 09:09 ET Forest Laboratories to Resume Clinical Development of Neuropathic Pain Indication for Memantine      Oct 17, 03 09:25 ET FDA Approves Namenda(TM) (memantine HCl) for the Treatment of Moderate to Severe Alzheimer's Disease      Oct 14, 03 08:17 ET Forest Laboratories Reports Earnings Per Share of $.49 for 2Q'04      Oct 07, 03 17:02 ET Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2004 Second Quarter Earnings   Oct 01, 03 16:13 ET Forest to Discontinue Development in U.S. of Dexloxiglumide for Irritable Bowel Syndrome (IBS)      Sep 29, 03 08:54 ET Lexapro(TM) Receives FDA Approvable Letter for the Treatment of Generalized Anxiety Disorder (GAD)      Sep 24, 03 17:01 ET FDA Advisory Committee Unanimously Votes That Data Submitted Supports Safety and Efficacy of Namenda(TM) (Memantine HCl) For Moderate to Severe Alzheimer's Disease      Sep 23, 03 08:00 ET Forest Laboratories, Inc. and H. Lundbeck A/S File Lawsuit Against Ivax Pharmaceuticals, Inc. for Patent Infringement      Sep 19, 03 08:00 ET New Study Demonstrates Lexapro(TM) Is As Effective As Effexor(R) XR And Is Significantly Better Tolerated      Aug 11, 03 10:10 ET Forest Laboratories Receives Notification of ANDA Filing for a Generic Equivalent of Lexapro(TM)      Jul 15, 03 08:14 ET Forest Laboratories Reports Fiscal First Quarter Earnings of $.48 Per Share      Jul 02, 03 12:52 ET Forest Laboratories, Inc. Sets Date And Conference Call for Fiscal 2004 First Quarter Earnings      Jun 19, 03 08:23 ET Combined Therapy of Memantine and Acetylcholinesterase Inhibitors For The Treatment of Mild to Moderate Alzheimer's Disease Did Not Demonstrate Statistically Significant Effects On Cognitive Or Global Outcome Compared To Placebo/Acetylcholinesterase Treat      May 22, 03 08:35 ET Lung Biopsy Study Shows Reduction in Inflammatory Markers in Both Large and Small Airways Following Treatment With Aerospan(TM)      May 21, 03 08:01 ET Severely Depressed Patients Treated With Escitalopram Show Significant Improvement Over Placebo      May 07, 03 08:51 ET Forest Announces That a Just Completed Clinical Study of Memantine For Neuropathic Pain Failed to Demonstrate a Statistically Significant Difference Versus Placebo      May 01, 03 08:05 ET Forest Laboratories Submits Application to Market Lexapro(TM) For the Treatment of Panic Disorder      Apr 22, 03 07:50 ET Forest Laboratories Reports Record Fiscal Fourth Quarter And Full Year Results      Apr 17, 03 13:06 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2003 Fourth Quarter Earnings      Apr 04, 03 08:30 ET Alzheimer's Researchers Report Improvement in Cognition Relative To Baseline in Patients Treated with Memantine and Donepezil      Mar 10, 03 08:31 ET New Study Concludes There Are No Pharmacokinetic Drug Interactions Between Memantine and Donepezil      Jan 30, 03 12:01 ET Forest Laboratories Announces Acceptance of Memanatine NDA Filing for the Treatment of Alzheimer's Disease      Jan 16, 03 08:01 ET Forest Laboratories Reports Record Fiscal Third Quarter Results      Jan 09, 03 11:20 ET Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2003 Third Quarter Earnings      Jan 02, 03 16:05 ET Forest Laboratories Will Exceed Estimates for Fiscal 2003 Third Quarter Sales and Earnings      Dec 20, 02 07:45 ET Forest Laboratories Submits New Drug Application For Investigational Alzheimer's Treatment Memantine      Dec 16, 02 08:25 ET Forest Laboratories, Inc. Announces Two-For-One Stock Split      Dec 11, 02 08:00 ET New Studies Show Lexapro(TM) Significantly Reduces Anxiety in Patients With Generalized Anxiety Disorder (GAD) Versus Placebo      Dec 09, 02 16:40 ET New Study Shows Improved Cognition Relative to Baseline for Alzheimer's Patients Treated With Investigational Memantine and Donepezil      Dec 06, 02 08:00 ET Forest Updates Status of Lercanidipine Regulatory Submission      Dec 02, 02 11:00 ET Lexapro(TM) Oral Solution Formulation Provides New Option for Depressed Patients      Nov 27, 02 08:35 ET Forest Laboratories Submits Application to Market Lexapro(TM) for the Treatment of Generalized Anxiety Disorder (GAD)   Nov 11, 02 08:00 ET Long-Term Study Suggests Patients on a New Anti-Hypertensive May Fare Better Than Those on Most Widely-Prescribed Treatment      Oct 22, 02 16:12 ET Forest Laboratories, Inc. Announces Stock Option Exercises and Sales by Certain Executive Officers      Oct 21, 02 09:24 ET Forest Laboratories Receives FDA Approvable Letter For Oxycodone HCl/Ibuprofen   Oct 15, 02 07:32 ET Forest Laboratories Reports Record Fiscal Second Quarter 2003 Results      Oct 04, 02 11:04 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2003 Second Quarter Earnings   Sep 30, 02 16:05 ET Forest Laboratories Will Exceed Estimates for Fiscal 2003 Second Quarter Sales and Earnings      Sep 23, 02 08:03 ET Forest Laboratories Withdraws NDA for Alzheimer's Agent Memantine And Will Refile and Amend to Include New Study      Sep 10, 02 08:48 ET Forest Laboratories Reports Positive Results of a Phase III Trial of Memantine For Alzheimer's Disease      Sep 05, 02 16:50 ET Forest Initiates 'EXCEED' Trial to Examine Effect of Lexapro(TM) on Quality of Life      08:01 ET Lexapro(TM) is Now Available in Pharmacies Nationwide For the Treatment of Major Depressive Disorder      Aug 29, 02 12:05 ET Lexapro(TM) Approved as Maintenance Treatment for Major Depressive Disorder      Aug 15, 02 08:45 ET Lexapro(TM), The Single-Isomer of Celexa(TM), Receives FDA Approval For the Treatment of Major Depression      Aug 09, 02 13:49 ET Forest Laboratories Issues Correction of CBS Report      Aug 06, 02 08:01 ET Forest Laboratories Receives Approvable Letter From FDA for Lercanidipine   Aug 01, 02 08:15 ET Forest Laboratories Announces Submission of New Drug Application For the Investigational Alzheimer's Treatment Memantine      Jul 22, 02 06:00 ET Treatment With Investigational Alzheimer's Medication, Memantine, Shown to Reduce Time and Cost Associated With Caregiving      Jul 17, 02 08:00 ET Forest Receives Six-Month Extension on Celexa(TM) After FDA Review of Pediatric Data      07:15 ET Forest Laboratories Reports Record Fiscal First Quarter Results      Jul 11, 02 11:44 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2003 First Quarter Earnings      Jul 02, 02 10:37 ET FDA Issues Non-Approvable Letter for Acamprosate      10:37 ET Forest Laboratories Will Exceed Estimates for Fiscal 2003 First Quarter Sales And Earnings      Jun 24, 02 03:00 ET Pre-Clinical Data Shed Light on the Potency of Lexapro(TM)      May 15, 02 09:02 ET New Data on Investigational Hypertension Treatment, Lercanidipine, Presented at Ash Meeting      May 10, 02 18:34 ET Forest Laboratories and Merck KGaA Announce Positive Outcome of FDA Advisory Committee's Review of Acamprosate Data      Apr 26, 02 08:01 ET FDA Grants Marketing Approval For Benicar (olmesartan medoxomil) For Treatment of Hypertension      Apr 24, 02 07:25 ET Forest Laboratories Reports Record Fiscal Fourth Quarter and Full Year Results      Apr 22, 02 13:33 ET Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2002 Fourth Quarter and Full Year Earnings      Mar 20, 02 09:03 ET Lexapro(TM) Significantly More Effective Than Placebo in Treating Generalized Anxiety, Social Anxiety, and Panic Disorders      Mar 13, 02 07:30 ET Forest Laboratories Announces Termination of Agreement for ML3000      Feb 27, 02 08:03 ET Forest Laboratories Announces Acceptance of The NDA Filing for Acamprosate for the Treatment of Alcohol Dependence      Feb 19, 02 13:50 ET Forest Laboratories Announces ML-3000 European Study Results      Jan 24, 02 10:34 ET Lexapro(TM), The Single-Isomer of Celexa(TM), Receives FDA Approvable Letter      Jan 15, 02 08:30 ET Forest Laboratories Reports Record Fiscal Third Quarter Results      Jan 07, 02 09:00 ET Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2002 Third Quarter Earnings      Dec 20, 01 16:54 ET Forest Laboratories Submits New Drug Application for Oxycodone HCl/Ibuprofen as Treatment of Moderate to Severe Pain      Dec 13, 01 08:31 ET Results of Escitalopram and Celexa(TM) Studies Presented at Major Scientific Conference      Dec 12, 01 08:30 ET Forest Laboratories Announces Agreement With Sankyo Pharma to Co-Promote Olmesartan Medoxomil      Oct 26, 01 16:08 ET First Expert Consensus Guidelines for the Treatment Of Geriatric Depression Published   Oct 23, 01 07:34 ET Forest Laboratories Announces Agreement For Alcohol Addiction Treatment      Oct 18, 01 09:04 ET Phase II Data Presented on Dexloxiglumide      Oct 16, 01 08:30 ET Forest Laboratories Reports Record Fiscal Second Quarter Results      Oct 09, 01 11:07 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2002 Second Quarter Earnings      Oct 02, 01 09:01 ET Forest Laboratories Submits New Drug Application For Lercanidipine as Treatment of Hypertension      Sep 21, 01 11:34 ET Forest Reaffirms Earnings Guidance for Fiscal 2002   Jul 17, 01 08:31 ET Forest Laboratories Reports Record Fiscal First Quarter Results   Jul 09, 01 10:55 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2002 First Quarter Earnings      Jul 05, 01 09:21 ET Results of a Pooled Analysis of Several Clinical Trials of Escitalopram, Citalopram, and Placebo Will Be Reported Today at World Congress of Biological Psychiatry Meeting   Jul 02, 01 08:30 ET Forest Laboratories Licenses Novel NMDA Receptor Antagonist from Merz + Co.   May 17, 01 08:30 ET FDA Issues Approvable Letter for Flunisolide HFA      May 10, 01 17:29 ET Two Studies Show Potential Effects of Investigational Alzheimer's Drug   May 09, 01 17:27 ET Results of Several Clinical Trials of Escitalopram, Citalopram, and Placebo, And Pooled Analyses of These Trials to Be Reported Today at American Psychiatric Association Meeting   May 05, 01 12:39 ET Escitalopram Data to be Presented at American Psychiatric Association Meeting      Apr 24, 01 08:30 ET Forest Laboratories Reports Record Fiscal Fourth Quarter and Full Year Results      Apr 18, 01 10:35 ET Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal Fourth Quarter and Full Year 2001 Earnings      Mar 26, 01 10:00 ET Forest Laboratories Submits New Drug Application for Escitalopram as Treatment of Depression      Jan 30, 01 09:29 ET Forest Laboratories Announces Product Developments For Memantine, Alvameline and Tiazac(R)      Jan 09, 01 12:11 ET Forest Laboratories, Inc. to Webcast Fiscal Third Quarter 2001 Earnings Conference Call      Dec 18, 00 08:35 ET Forest Laboratories, Inc. Announces Two-for-One Stock Split      Nov 08, 00 03:30 ET Forest Laboratories Announces Agreement With Recordati for a License to Lercanidipine      Nov 06, 00 15:56 ET Forest Laboratories Announces the Appointment of Charles E. Triano as Vice President of Investor Relations      Oct 17, 00 10:03 ET Forest Laboratories Reports Record Fiscal Second Quarter Results      Oct 11, 00 16:33 ET Forest Laboratories Reports Fiscal Second Quarter Results   Aug 29, 00 09:05 ET Forest Laboratories Announces Agreement With NPS Allelix For a License to ALX-0646   Aug 07, 00 09:18 ET Forest Laboratories Announces Agreement With Rotta Research For License Of Dexloxiglumide   Jul 18, 00 08:32 ET Forest Laboratories Reports Fiscal First Quarter Results   Jul 17, 00 14:52 ET Forest Laboratories Reports Fiscal First Quarter Results   Jul 14, 00 11:05 ET Forest Laboratories Reports Fiscal First Quarter Results   Jun 29, 00 09:07 ET Forest Laboratories Announces Agreement With Merz & Co. for License to Memantine   May 12, 00 08:30 ET Forest Laboratories Announces Termination of Celexa(TM) Co-Promotion Agreement With the Warner-Lambert Company   May 02, 00 08:31 ET Forest Laboratories Reports Fourth Quarter and Fiscal 2000 Results   Apr 11, 00 08:30 ET Forest Laboratories Announces Agreement with Merckle GmbH for Osteoarthritis Drug   Jan 18, 00 08:31 ET Forest Laboratories Reports Fiscal Third Quarter Results   Nov 15, 99 16:04 ET Forest Laboratories Clarifies Future of Celexa(TM) Marketing   Oct 19, 99 08:31 ET Forest Laboratories Reports Fiscal Second Quarter Results   Sep 28, 99 08:30 ET Forest Laboratories Applies for Listing on the New York Stock Exchange   Jul 22, 99 09:06 ET Forest Laboratories Restructures Climara(R) Agreement   Jul 20, 99 08:32 ET Forest Laboratories Reports Fiscal First Quarter Results   Jun 30, 99 09:22 ET Infasurf(R) Does Not Infringe on Survanta(R) Patents   May 04, 99 08:30 ET Forest Laboratories Reports Fourth Quarter and Fiscal 1999 Results   Mar 24, 99 11:18 ET Forest Laboratories Response to FDA Warning Letter   Jan 19, 99 08:30 ET Forest Laboratories Reports Fiscal Third Quarter Results   Nov 30, 98 17:02 ET Forest Laboratories Announces Retirement of Executive Vice President And Management Changes   Nov 18, 98 09:00 ET Forest Laboratories Receives a Non-Approvable Letter From the FDA on Synapton(TM)   Oct 21, 98 08:30 ET Forest Laboratories Reports Fiscal Second Quarter Results   Sep 14, 98 09:02 ET Forest Laboratories' Infasurf(R) Found To Infringe Survanta(R)'s Patents; Launch Postponed   Aug 19, 98 08:53 ET Forest Laboratories' Licensed M1 Agonist Not Effective in Alzheimer's Disease; Studies to Continue for Other Indications   Jul 21, 98 08:29 ET Forest Laboratories Reports Fiscal First Quarter Results   Jul 20, 98 08:22 ET FDA Approves Celexa(TM) for the Treatment of Depression - A Leading SSRI in Europe, Now Available in the U.S. -   May 13, 98 09:10 ET Forest Laboratories' Celexa(TM) Antidepressant Found Approvable by the FDA   May 05, 98 00:00 ET Forest Laboratories Reports Fourth Quarter and Fiscal 1998 Results   Feb 24, 98 18:01 ET Forest Laboratories Announces the Election of New Directors and Management Appointments   Feb 23, 98 17:59 ET Forest Laboratories Announces Two-For-One Stock Split   Feb 11, 98 17:54 ET Forest Laboratories Announces the Filing of Supplemental New Drug Applications for Aerobid(R) Once a Day Dosing and Aeropak   Feb 03, 98 17:49 ET Forest Laboratories Announces Approval of Tiazac(R) For Angina